165 related articles for article (PubMed ID: 20818880)
1. Treating cancer by targeting the immune system.
Hwu P
N Engl J Med; 2010 Aug; 363(8):779-81. PubMed ID: 20818880
[No Abstract] [Full Text] [Related]
2. Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS; O'Day SJ; McDermott DF; Weber RW; Sosman JA; Haanen JB; Gonzalez R; Robert C; Schadendorf D; Hassel JC; Akerley W; van den Eertwegh AJ; Lutzky J; Lorigan P; Vaubel JM; Linette GP; Hogg D; Ottensmeier CH; Lebbé C; Peschel C; Quirt I; Clark JI; Wolchok JD; Weber JS; Tian J; Yellin MJ; Nichol GM; Hoos A; Urba WJ
N Engl J Med; 2010 Aug; 363(8):711-23. PubMed ID: 20525992
[TBL] [Abstract][Full Text] [Related]
3. Diarrhea from ipilimumab in melanoma.
Schwartz JD
N Engl J Med; 2010 Dec; 363(23):2262; author reply 2262-3. PubMed ID: 21121842
[No Abstract] [Full Text] [Related]
4. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
5. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
Tarhini AA; Kirkwood JM
Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab.
Sondak VK; Smalley KS; Kudchadkar R; Grippon S; Kirkpatrick P
Nat Rev Drug Discov; 2011 Jun; 10(6):411-2. PubMed ID: 21629286
[No Abstract] [Full Text] [Related]
7. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
Robert C; Mateus C
Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
[TBL] [Abstract][Full Text] [Related]
8. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
Akhtari M; Waller EK; Jaye DL; Lawson DH; Ibrahim R; Papadopoulos NE; Arellano ML
J Immunother; 2009 Apr; 32(3):322-4. PubMed ID: 19242368
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
10. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
11. Targeting metastatic melanoma.
Poust J
Am J Health Syst Pharm; 2008 Dec; 65(24 Suppl 9):S9-S15. PubMed ID: 19052265
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune inflammatory myopathy after treatment with ipilimumab.
Hunter G; Voll C; Robinson CA
Can J Neurol Sci; 2009 Jul; 36(4):518-20. PubMed ID: 19650371
[No Abstract] [Full Text] [Related]
13. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
Lens M; Ferrucci PF; Testori A
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):105-13. PubMed ID: 18537753
[TBL] [Abstract][Full Text] [Related]
14. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
Wilgenhof S; Neyns B
Ann Oncol; 2011 Apr; 22(4):991-993. PubMed ID: 21357649
[No Abstract] [Full Text] [Related]
15. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
16. The conquest of melanoma by immunotherapy.
Lejeune FJ
Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
[No Abstract] [Full Text] [Related]
17. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
18. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
Gordon IO; Wade T; Chin K; Dickstein J; Gajewski TF
Cancer Immunol Immunother; 2009 Aug; 58(8):1351-3. PubMed ID: 19052742
[No Abstract] [Full Text] [Related]
19. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
20. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
